Ulla Lepola

Summary

Country: Finland

Publications

  1. ncbi [Sexual dysfunction in mental disorders]
    Ulla Lepola
    HY:n psykiatrian klinikka Lapinlahdentie, 00180 Helsinki
    Duodecim 119:255-9. 2003
  2. ncbi Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder
    Ulla Lepola
    Kuopio Psychiatric Research Clinic, Kuopio, Finland
    J Clin Psychiatry 64:654-62. 2003
  3. ncbi Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder
    Ulla Lepola
    Kuopion Psykiatripalvelu OY Psychiatric Research, Clinic of Kuopio, Kuopio, Finland
    Int Clin Psychopharmacol 19:149-55. 2004
  4. ncbi A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder
    Mark H Pollack
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Depress Anxiety 24:1-14. 2007
  5. ncbi [Antidepressant treatment and psychiatric emergency services]
    Esa Leinonen
    Tampereen yliopisto, psykiatrian opetusala
    Duodecim 118:307-11. 2002
  6. ncbi Psychiatric drug trials and placebo
    Hannu Koponen
    Department of Psychiatry, University of Oulu, Finland
    Nord J Psychiatry 59:233-7. 2005
  7. ncbi Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study
    Hannu Naukkarinen
    Department of Psychiatry, University of Helsinki, Box 320 Lapinlahdentie, FIN 00180, HUCH, Helsinki, Finland
    Eur Neuropsychopharmacol 15:617-23. 2005
  8. ncbi Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine
    Christer Allgulander
    Karolinska Institutet, The Neurotec Department, Section of Psychiatry, Stockholm, Sweden
    Hum Psychopharmacol 19:387-96. 2004
  9. ncbi Controlled-release paroxetine in the treatment of patients with social anxiety disorder
    Ulla Lepola
    Department of Psychiatry, University of Helsinki, Helsinki, Finland
    J Clin Psychiatry 65:222-9. 2004
  10. ncbi Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
    Patrice Boyer
    University of Ottawa, Institute of Mental Health Research, Ottawa, Ontario, Canada
    Int Clin Psychopharmacol 23:243-53. 2008

Collaborators

Detail Information

Publications10

  1. ncbi [Sexual dysfunction in mental disorders]
    Ulla Lepola
    HY:n psykiatrian klinikka Lapinlahdentie, 00180 Helsinki
    Duodecim 119:255-9. 2003
  2. ncbi Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder
    Ulla Lepola
    Kuopio Psychiatric Research Clinic, Kuopio, Finland
    J Clin Psychiatry 64:654-62. 2003
    ..To evaluate the efficacy and tolerability of sertraline and imipramine in patients with comorbid panic disorder and major depressive disorder...
  3. ncbi Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder
    Ulla Lepola
    Kuopion Psykiatripalvelu OY Psychiatric Research, Clinic of Kuopio, Kuopio, Finland
    Int Clin Psychopharmacol 19:149-55. 2004
    ..05, LOCF/OC). Escitalopram showed consistently superior efficacy compared to citalopram in the treatment of moderate to severe MDD on all efficacy parameters, and was similarly well tolerated...
  4. ncbi A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder
    Mark H Pollack
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Depress Anxiety 24:1-14. 2007
    ..Adverse events were mild or moderate and similar between active treatment groups. Venlafaxine ER and paroxetine were effective and well tolerated in the treatment of panic disorder...
  5. ncbi [Antidepressant treatment and psychiatric emergency services]
    Esa Leinonen
    Tampereen yliopisto, psykiatrian opetusala
    Duodecim 118:307-11. 2002
  6. ncbi Psychiatric drug trials and placebo
    Hannu Koponen
    Department of Psychiatry, University of Oulu, Finland
    Nord J Psychiatry 59:233-7. 2005
    ..In this systematic review, the present guidelines for developing new compounds for psychiatric disorders are discussed...
  7. ncbi Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study
    Hannu Naukkarinen
    Department of Psychiatry, University of Helsinki, Box 320 Lapinlahdentie, FIN 00180, HUCH, Helsinki, Finland
    Eur Neuropsychopharmacol 15:617-23. 2005
    ..Deramciclane was safe and well-tolerated up to the 60 mg/day dose over an 8-week period...
  8. ncbi Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine
    Christer Allgulander
    Karolinska Institutet, The Neurotec Department, Section of Psychiatry, Stockholm, Sweden
    Hum Psychopharmacol 19:387-96. 2004
    ..Both active treatments were generally well tolerated and were associated with a similar incidence of adverse events. This study shows that venlafaxine ER is an effective, safe and well-tolerated drug treatment for SAD...
  9. ncbi Controlled-release paroxetine in the treatment of patients with social anxiety disorder
    Ulla Lepola
    Department of Psychiatry, University of Helsinki, Helsinki, Finland
    J Clin Psychiatry 65:222-9. 2004
    ..This favorable tolerability profile may enable more patients to experience the benefits of effective therapy...
  10. ncbi Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
    Patrice Boyer
    University of Ottawa, Institute of Mental Health Research, Ottawa, Ontario, Canada
    Int Clin Psychopharmacol 23:243-53. 2008
    ..Fixed doses of desvenlafaxine 50 and 100 mg/day are safe, generally well tolerated, and effective at a clinically relevant level for the treatment of MDD...